药易购：前三季度实现营收32.42亿元 积极推进战略转型

Core Insights - The company reported a revenue of 3.242 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 0.21%, while the net profit attributable to shareholders was -8.3565 million yuan, a decline of 159.98% [1] - In Q3 alone, the company achieved a revenue of 1.085 billion yuan, marking a year-on-year increase of 7.41% [1] Financial Performance - The revenue performance for the first three quarters was stable, but the profit was under short-term pressure due to significant impacts from income tax expenses and goodwill impairment [1] - The increase in income tax expenses was primarily due to profit increases in some subsidiaries and changes in business models, leading to the reversal of previously recognized deferred tax assets [1] - Goodwill impairment was noted in the subsidiary Jingcheng Mingyi, prompting a goodwill impairment test at the end of the period [1] - Sales expenses increased by 42.47% year-on-year, driven by rapid growth in the e-commerce business and increased online promotion expenditures while maintaining controllable profits [1] Strategic Initiatives - The company is actively pursuing strategic transformation, focusing on the outpatient market to seek breakthroughs amid industry policy and market competition challenges [2] - Despite short-term profit pressures, the company has made significant progress in strategic transformation and ecological layout [2] - The digital empowerment platform (such as Yaojuli) and the C-end full-domain reach network are gradually building competitive barriers in the industry [2] - Continuous investment in innovative fields through industrial funds and data asset operations is aimed at long-term growth [2] - The company is expected to gain a competitive edge in the outpatient market's full-chain services as the ecological closed loop accelerates and the proportion of high-margin businesses increases [2]